Related Experiment Videos
[Extravasation of cytotoxic agents]
Elisabeth Nogler-Semenitz1, Ines Mader, Patrizia Fürst-Weger
1Anstaltsapotheke, Landeskrankenhaus Universitätskliniken Innsbruck, Osterreich.
Wiener Klinische Wochenschrift
|July 9, 2004
Summary
Understanding extravasation risk factors and management is crucial for preventing chemotherapy-related tissue damage. Prompt and appropriate interventions, including specific antidotes, can mitigate severe complications from antineoplastic agents.
Area of Science:
- Oncology
- Pharmacology
- Toxicology
Context:
- Antineoplastic agents, used in cancer therapy, can cause severe tissue damage upon extravasation (leakage into surrounding tissues).
- Risk factors for extravasation are multifactorial, encompassing patient-related and iatrogenic elements.
- Effective prevention and management strategies are essential due to potential complications.
Purpose:
- To review risk factors, classification of agents, and management strategies for antineoplastic extravasation.
- To evaluate the evidence for various interventions, including antidotes and topical measures.
- To highlight the need for improved knowledge and standardized protocols.
Summary:
- Antineoplastic agents pose a risk of extravasation injury to healthy tissues.
- Classification includes vesicant, irritant, and non-vesicant agents, guiding emergency measures.
- Evidence supports specific antidotes like dimethylsulfoxide or hyaluronidase, while others like corticosteroids remain controversial.
Impact:
- Improved understanding of extravasation risks can enhance patient safety during chemotherapy.
- Standardized protocols and evidence-based interventions can minimize tissue damage and improve patient outcomes.
- Further research is needed to address knowledge gaps in managing extravasation from various cytotoxic agents.